ICA can also alleviate RA symptoms by inhibiting osteoclast markers (e.g., β3 integrin, cathepsin K, MMP-9) and suppressing IL-17 production via Th17 cells and STAT3, thereby adjusting the OPG/RANKL balance. Here, CTSK is linked to rheumatoid arthritis.